Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamiid - epilepsia - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

eisai gmbh - rufinamide - epilepsia - antiepileptics, - inovelon on näidustatud adjunctive ravi ravi krambid seotud lennox gastaut sündroomiga patsientidel, 4-aastased ja vanemad.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemilised preparaadid - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemilised preparaadid - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - daclatasvirdihüdrokloriid - c-hepatiit, krooniline - viirusevastased ravimid süsteemseks kasutamiseks - daklinza on näidustatud kombinatsioonis teiste kroonilise hepatiit c viiruse (hcv) nakkuse raviks mõeldud ravimitega täiskasvanutel (vt lõigud 4. 2, 4. 4 ja 5. sest hcv genotüüp konkreetne tegevus, vt punktid 4. 4 ja 5.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

pfizer limited  - metaflumizone, amitraz - nahaparasiidi paikseks kasutamiseks, sh. insektitsiidid - koerad - kirblaste (ctenocephalides canis ja c) nakkuste raviks ja vältimiseks. felis) ja puukide (ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus, dermacentor reticulatus ja dermacentor variabilis), ja ravi demodicosis (põhjustatud demodex spp. ) ja täid (trichodectes canis) koertel. veterinaarravimit saab kasutada kirbuallergia dermatiidi (fad) ravistrateegia osana..

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslikarbasepiinatsetaat - epilepsia - antiepileptics, - zebinix on näidustatud lisaravina täiskasvanutel, noorukitel ja lastel üle 6 aasta, koos sekundaarse generaliseerumisega või ilma partsiaalsete hoogude.

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituksimab - lymphoma, non-hodgkin; microscopic polyangiitis; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis - antineoplastilised ained - rituzena on näidatud täiskasvanute jaoks järgmisi andmeid:mitte-hodgkini lümfoom (nhl)rituzena on näidustatud raviks eelnevalt ravimata patsientidel iii etapp iv follikulaarne lümfoom kombinatsioonis keemiaraviga. rituzena monotherapy on näidustatud patsientidele, kellel iii etapp iv follikulaarne lümfoom, kes on kemo vastupidavad või on oma teine või järgmine hakkavad pärast keemiaravi. rituzena on näidustatud patsientide raviks cd20 positiivne hajus suur b-rakkude mitte hodgkini lümfoom koos karbonaad (tsüklofosfamiid, doxorubicin, vincristine, prednisoloon) keemiaravi. krooniline lümfoidne leukeemia (cll)rituzena kombinatsioonis keemiaraviga on näidustatud patsientide raviks eelnevalt ravimata ja taastekkinud/tulekindlad cll. ainult piiratud andmed on saadaval efektiivsust ja ohutust patsientidel, eelnevalt ravitud monoklonaalsete antikehadega (sealhulgas rituzenaor patsientidel, tulekindlad, et eelmise rituzena pluss kemoteraapiat. granulomatosis koos polyangiitis ja mikroskoopilised polyangiitisrituzena, koos glucocorticoids, on näidustatud remissiooni induktsioon täiskasvanud patsientidel, kellel on raske, aktiivse granulomatosis koos polyangiitis (wegener) (gpa) ja mikroskoopilised polyangiitis (mpa).